Abstract
1. In a fourway double-blind placebo controlled study, the effects of cilazapril, a new angiotensin converting enzyme inhibitor, on renal function and the responses to intravenous frusemide were studied in a group of twelve salt depleted male volunteers. 2. Cilazapril produced an increase in effective renal plasma flow and urinary output of prostaglandin E2 metabolite (PGE2-M) but no effect on sodium, potassium or water excretion. 3. Pretreatment with cilazapril antagonised the effects of frusemide on glomerular filtration, PGE2-M and sodium excretion.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
-
Cilazapril
-
Dinoprostone / urine
-
Double-Blind Method
-
Furosemide / administration & dosage
-
Furosemide / pharmacology*
-
Glomerular Filtration Rate / drug effects
-
Humans
-
Injections, Intravenous
-
Kidney / drug effects*
-
Male
-
Pyridazines / administration & dosage
-
Pyridazines / pharmacology*
-
Renin / blood
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Pyridazines
-
Cilazapril
-
Furosemide
-
Renin
-
Dinoprostone